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EDWARD D. FROHLICH, MD, FACC
Nell' Orleans, Louisiana
Only 25 years ago, the field of hypertension was chal-
lenged by retrospective clinical data and epidemiologic
information suggesting that an elevated arterial pressure
is a major risk factor for enhanced cardiovascular mor-
bidity and mortality. Not only was antihypertensive ther-
apy looked on by many as dangerous and fraught with
severe and undesirable side effects, but its validity in
reversing the course of disease was not yet demonstrated.
This review discusses the dramatic new information
amassed over the past 25 years that points to the new
physiologic and clinical concepts concerning hyperten-
An invitation to review the past 25 years of achievement in
the area of the hypertensive diseases for the inaugural issue
of the Journal of the American College of Cardiology is a
great honor. Over this past quarter-century, there has been
an array of outstanding successes and achievements, many
by fellow members of the College. During these years,
major important and fundamental concepts were introduced
concerning the mechanisms underlying the control of arterial
blood pressure and the pathogenesis of hypertensive dis-
eases. Diagnostic techniques were introduced that ushered
in the concept of selective angiography and organ scans.
These, together with novel methods for measuring vaso-
active substances and hormones, have provided new di-
mensions for assessing body function.
Over these past 25 years, antihypertensive drugs have
been synthesized and provide the means to dissect the neph-
ron, the autonomic nervous system and even vascular smooth
muscle machinery with chemical precision. These agents
have improved in sophistication from the massive "block-
busters" of the ganglionic blocking agents to the chemical
"rifle bullets" that target specific intracellular and cellular
wall chemical systems with remarkable accuracy. More-
over, these new pharmacologic compounds have provided
the way for new cardiovascular therapeutic concepts in-
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sion. It considers impressive new diagnostic techniques
and methods designed to identify secondary forms of
hypertension and target organ involvement. In sum-
mary, it outlines the feasibility of reversing overall (and
cardiovascular) morbidity and mortality with an array
of antihypertensive agents that provide the therapeutic
ability to suppress most pathophysiologic pressor mech-
anisms of hypertensive disease. The lesson is clear: hy-
pertension provides the greatest available challenge to
the new era of preventive cardiology in the 21st century.
eluding the role of sodium and water in volume loading and
unloading in heart failure and shock, the reduction of ven-
tricular afterload in heart failure. pharmocologic catechol-
amine receptor inhibition with its implications in treatment
of arrhythmias, the inhibition of the renin-angiotensin sys-
tem in heart failure and the blockade of adrenergic function
in the treatment of ischemic heart disease. The feasibility
of multicenter clinical trials was demonstrated and the safety
and efficacy of antihypertensive therapy were established,
heralding a new era of preventive cardiology and the be-
ginnings of a reversal of the major cause of death in the
United States and the western world---eardiovascular disease.
These. indeed. have been years of achievement in the
field of hypertension, and the gains have had a major impact
not only on the entire discipline of cardiovascular medicine,
but on overall biologic knowledge and morbidity and mor-
tality worldwide. This review is not intended to provide an
all inclusive review of the major achievements in the hy-
pertension area. Many textbooks (1-4) published in recent
years have been oriented to this purpose. It is intended to
provide the interested reader with an overview of an exciting
and productive area of cardiovascular medicine, the con-
tributions of which continue to be realized by other branches
of medicine.
Epidemiology
It was in the area of hypertensive diseases that many epi-
demiologic studies with cardiovascular and broader medical
implications had major impact over these 25 years. These
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studies have I) demonstrat ed the overall prevalence of hy-
pertension in the community (5 .6); 2) provided definiti on
of the levels of arterial blood pressure that carry the greatest
risk of increased morb idity and mortality (7-9); 3) defined
racial groups that seem to be at greater risk (5.10.11) : 4 )
demonstrated interacting factors associated with the elevated
arterial pressure that confer this increase d risk of cardio-
vasc ular morbidity and mortal ity: and 5) point ed the way
to more logical approaches to treating populations and . one
hopes. to programs of prevent ion .
Definition. Studies reach ing the ir peak of productivity
in the early 1960s pointed to the unimodal and continuous
distribution of arterial pressure levels in any population group
(\2). However. it was the actuarial studies performed by
insurance companies that demonstrated. with clear signifi-
cance . the prognostic implications of pressure that exceeded
certain levels (\3.14). Although these data demonstrated
the prognostic import of the elevated arterial pressure. they.
of course. could not imply that reduction of pressure would
alter long-term survival of person s with high pressures. Th is
was the challenge for future prospective clini cal trials .
Nevertheless. they did reveal the necessity for additi onal
work to demonstrate those pressure levels that carry the
greatest risk. In the earl y 1960s. the long-term progn ostic
Framingham Study (15 ) was begun. which provided much
of the impetus for other studies worldwide that identified
the factors that increase cardi ovascular morbidity and mor-
tal ity . The early reports from Framingham demon strated that
the higher the pressure. systolic or diastol ic . the greater the
cardiovas cular risk (7). These studies also defined the risk
in subpopulation groups: that in general. men have higher
arterial pressures than women (at least until the menop ause)
(16); that there was a greater prevalence of higher pressures
in the black population than in the white . and that at any
age there was a greater prev alence of black patients with
high pressures than of white patients (17); and that hyper-
tension was the major cau se of congestive heart failure in
both men and women (18). Data also indicated that the most
common form of hypertensive disease. essential hyperten-
sion, most likely has its on set in youth and that the blood
pressure level tracks with the individual throu ghout adoles-
cence into adulthood, eventually to surface as clin ical hy-
pertension in midlife or earlier (19 .20). The se studies were
complemented , confirmed, enchanced and supported by a
large number of studies all over the world. and subsequently
supported by prospectively designed studies aimed to dem-
onstrate that a reduction of arterial pressure would reverse
this increasing incidence of cardiovascular morbidity and
mortality .
Role of dietary sodium. Studies conducted exper imen-
tally in the laboratory (2 1) have pointed to the role of the
sodium ion in elevated arterial pressure . These studies have
been supported only in part by epidemiologic investigations
(22) . Nevertheless. they indicated that the quantity of dietary
sodium ingested by different popul ations varies tremen-
dously around the world and that there seems to be an
important direct relation between the amount of salt ingested
in a particular popul ation and the prevalence of hypertension
(23.24) . However. in those popul ations that ingest little
sodium (about 10 mEq daily). hypertension seems to be
nonexistent (25) and . if the dietary sodium content is re-
stricted to less than 70 mEq daily . there see ms to be no
" normal" increase in systolic or diastolic pressure with
agi ng (26) . These studies suggest that the problem of hy-
pertension seems to be grea ter in so-called western ized. in-
dustrialized or "acculturated" socie ties (27) . The role of
sodium in the pathogenesis of hypertension continues to be
under intensive epidemiologic . clinical and experimental
investigation: moreover. its spec ific mechanism in elevating
arterial pressure requires additional study. It is. therefore .
premature to 'conclude thai dietary sodium restriction will
prevent the development of hypert ension: however. dietary
sodium restri ction is recomm ended for pat ients with hy-
perte nsion as an important therapeutic adjunct (28) .
Other associations. Epidemio logic studies also have
demonstrated a more than chance associ ation between other
diseases and hypert ension. There is a grea ter prevalence of
hypertension in patient s with altered carbohydrate metab-
olism and diabetes mellitus (29-32). And. conversely. there
is a greater prevalen ce of diabete s mellitus and carbohydrate
intolerance in patients with hypertension than in the genera l
popul ation (3 1.32). The precise mechanism explaining this
assoc iation has not yet been offered. and one study has even
challenged this long-held ass umption (33).
Other reports (34.35) have shown a greater prevalence
of elevated uric acid levels in patients with hypertension
than in the general population . The reason for this asso-
cia tion also remains unexplained . but a recent study (36)
suggested that the elevated serum uric acid may reflect early
hypertensive vascular dise ase changes in the renal circula-
tion rather than altered purin e metabolism; however . both
alterations could provide the explanation. A third metabol ic
abnormality- elevated levels of lipids and lipoproteins
(5 ,7.9,37)-has been found in patients with hypertension.
Among other alterations that characterize the ' 'profile"
ofa population ofhypertensive patients are increased body
mass and a faster heart rate . With respect to the overweight
characteristic . there is a greater prevalence of hypertension
in a population of obe se persons (38 .39). and patients with
hypert ension seem to weigh more than comparable nor-
motensive persons (40,4 1). The faster heart rate in pat ients
with each form of hypertension (42) is an intriguing phys-
iologic finding becau se one would ex pect heart rate to be
slower as arterial pressure increases . Whether this is a re-
flection of the "reset baroreceptor mechan ism " in experi -
mental hypertension (43) or wheth er it repre sents a patho-
genetic mechanism that init iates the hypertensive process
must also be resolved . Each of the areas cited has been
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Table 1. Mechanisms That Control Arterial Pressure
suggested through epidemiologic investigations and each is
under intensive clinical and experimental study. Finally,
these and other factors (including cigarette smoking, per-
sonality type and alterations of other dietary ionic constit-
uents, certain foods, chemicals and drugs) have been shown
not only to participate in the hypertensive process but also
to be associated with increasing morbidity and mortality
from other cardiovascular diseases (44.45).
Pathophysiology
Over these past 25 years, there have been tremendous gains
in knowledgeof the regulationof arterial pressure. This new
information has contributed much to our understanding of
the pathophysiology of hypertensive diseases and other car-
diovascular illnesses. Currently, most workers in this area
conceive of essential hypertension as a multifactorialdisease
that is brought about by certain inborn hereditary, genetic
predisposing mechanisms that could interact with the myriad
of pathogenetic pressor and depressor physiologic factors
(46.47). Some reports (48.49) indicate that identifi able clin-
ical causes or types of secondary hypertension (for example,
aortic coarctation, renal artery disease, adrenal adenomas.
renal parenchymal disease) represent a very small proportion
of the overall population of hypertensive patients. How-
ever, with the overall prevalence of hypertension (60 million
Americans) reported in the most recent population studies
(50), even a 3 to 5% proportion represents upward of 3
million persons (far more than the total number of patients
with muscular dystrophy, multiple sclerosis, subaortic ste-
nosis or hemophilia, and possibly as many patientsas having
homozygous sickle cell anemia). And, most important, some
of these persons have remediable forms of hypertension.
An important benefitderived from studies of patientswith
secondary forms of hypertension has been an improved un-
derstanding of the mechanisms that control and maintain
arterial pressure (Table I). It therefore follows that ability
to assess participation of certain physiologic mechanisms
may lead to improved means to establish diagnosis and to
introduce more specific therapy.
Circulatory autoregulation. In recent years, several
pathogenetic concepts have been advanced concerning the
hemodynamic and other mechanisms underlying the path-
ogenesis and elaboration of hypertension. Notable among
I. Autoregulatory and hemodynamic
2. Mechanical factors
3. Neural mechanisms
4. Catecholamines
5. Renopressor system
6. Hormonal mechanisms
7. Volume mechanisms
8. Sodium interrelations
9. Depressor mechanisms
these were the concepts suggested by Borst (51). Ledingham
(52) and Guyton (53) and their co-workers that intrinsic in
the pathogenesis of essential hypertensive disease is an al-
tered handlingof circulating volume that transiently expands
the circulation, increases the cardiac output andarterial pres-
sure and permits a circulatory adaptation (that is, autoreg-
ulation) which eventually results in a state of maintained
higher pressure that is then associated with an increased
total peripheral resistance and normal cardiac output (54).
These concepts have received considerable support through
experimental studies, although expanded intravascular vol-
ume in essential hypertension has not been documented,
particularly early in essential hypertensive disease; in fact.
the contrary was observed (55.56). Indeed, clinical studies
have demonstrated increased cardiac output in the early
stages of hypertension (55,57). as well as in more severe
disease (58). Nevertheless. it is possible that a circulatory
autoregulatory process may occur without an expanded in-
travascular volume and increased cardiac output. This could
be achieved if a normal (or even contracted) intravascular
volume is associated with a normal cardiac output that is
maintained through increased peripheral venomotor tone and
mean circulatory filling pressure that increase venous return
to the heart (59). In fact, hypertension developed experi-
mentally in the presence of a reduced or normal intravascular
volume and cardiac output when the animals were pretreated
with beta-adrenergic receptor blocking drugs (60) or when
dietary sodium was restricted (61.62). Thus, the net hemo-
dynamic effect is the same as if a normal venomotor tone
were associated with an expanded intravascular volume: an
increased mean circulatory fi lling pressure and reduced vas-
cular (postcapillary) compliance (63,64). These same find-
ings of increased arteriolar and venular vascular tone have
been shown in a variety of clinical (essential, renovascular)
(65) and experimental (spontaneously hypertensive rats and
Goldblatt hypertensive rats) situations (63,64).
Adrenergic factors. An alternative pathogenetic expla-
nation might be that the increased venomotor and arteriolar
tone may be producedby adrenergic stimulation (48,57,66).
This mechanism is also compatible with the findings of a
faster heart rate, increased cardiac output and increased
myocardial contractility early in the developmental stages
of hypertension (57.67) and even later in the disease (58).
Just how this increased adrenergic input to the cardiovas-
cular system develops remains to be demonstrated: it might
be related to supersensitivity of neurohumoral agents (nor-
epinephrine. for example) to the sodium ion (68), to certain
defects in catecholamine metabolism or release (69) or even
to central stimulation of adrenergic output from the brain
by angiotensin (70).
Other work has shown that plasma catecholamin e levels
increase as arterial pressure rises in patients with essential
hypertension (71), but this relation may be affected by age,
race, sodium and water balance. as well as by other factors
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(72). Further. in some patients with mild essential hyper-
tension there may be an increased responsiveness of vessels
(73) and heart (74) to adrenergic agonists, as well as in-
creased plasma levels of catecholamines (75,76) and cyclic
adenosine monophosphate (77). With development of ra-
dioenzymatic methods for the measurement of plasma cate-
cholamine levels in small samples of blood. the role of
adrenergic participation in essential hypertension should be
further clarified (78).
Renin-angiotensin system. The latter hypothesis opens
discussion of the very active area of clinical and experi-
mental investigation over these past two and one-half dec-
ades: the role of the renin-angiotensin system in the path-
ogenesis of hypertension. These studies have demonstrated
the feasibility of measurement of each of the components
of this biochemical system (79-82). Until this was feasible.
evidence of the relation of this mechanism to the patho-
genesis of renovascular hypertension was only circumstan-
tial. Now it is well known that in patients with renovascular
hypertension, there are significant increases in plasma renin
activity in the venous blood from the affected kidney (83-
85). Moreover, pharmacologic interventions are available
that can inhibit the release of renin from the kidney (86-
88). arrest the biogenesis of angiotensin II (89-91) or in-
terfere with the vascular response to angiotensin II stimu-
lation (92.93) and control arterial pressure under a variety
of situations that may inhibit the renopressor system. It is
still not known why these therapeutic agents also reduce
arterial pressure in patients with normal renin or low renin
essential hypertension (94.95).
Studies have been concerned with characterizing the role
of the renopressor system in the pathogenesis of essential
hypertension through the elucidation of the magnitude of
plasma renin activity in these patients with respect to ap-
propriate sodium loading and aldosterone secretory and ex-
cretory responses (96.97). These studies suggested that per-
haps patients with high plasma renin activity have certain
prognostic characteristics (more severe course of disease.
more complications, for example) and certain therapeutic
prognostic indexes (98), whereas low plasma renin activity
suggests other prognostic and therapeutic factors. Although
the practical therapeutic lesson is that reduction of arterial
pressure through suppression of whatever physiologic pres-
sor mechanism seems to be participating is of paramount
importance, it does make clinical sense that the most specific
form of therapy with the fewest side effects would be the
most logical means to achieve that pressure control. To this
end. studies have shown that adrenergic- or angiotensin-
inhibiting therapy may be of greatest value in patients with
increased plasma renin activity (99.100) or evidence of greater
adrenergic input (hyperdynamic circulation) (101). and that
patients with the lowest plasma renin activity may be more
volume-dependent or will respond better to volume-con-
traction therapy (102 l.
Also known is the great interdependence of physiologic
mechanisms; it is possible that in those patients with higher
levels of plasma renin activity who most likely have greater
participation of the renopressor system, there is a normal
stimulation of certain brainstem centers that provide adren-
ergic input to the cardiovascular system (70). This. in turn.
would provide further stimulation of the renal juxtaglo-
merular apparatus to release more renin. thereby maintain-
ing the cycle of disease. Thus. it is possible that hyperten-
sion (essential hypertension as well as renovascular) may
be initiated through an increased release of renin from the
kidney or that it might be maintained through participation
of this system.
Aldosterone. Early in this period under discussion were
the exciting reports of Conn (103) and others (104.105) that
the very potent mineralocorticoid aldosterone was etiolog-
ically responsible for one form of secondary hypertension.
In patients with this condition. the hypertension was re-
versed with surgical removal of the adrenal adenoma: how-
ever. subsequent reports indicated that in some patients with
primary hyperaldosteronism. hypertension is not reversible.
These patients seem to have bilateral adrenal hyperplasia
(of the zona glomerulosal with hyperaldosteronism (106.107)
or. additionally, essential hypertension.
Another area of clinical controversy was related to the
observation ofnormokalemic primary aldosteronism and the
possibility that with this additional compounding problem
hypertension may be far more prevalent than previously
considered (!08). This concern was particularly pertinent
in view of the relatively contemporaneous observation of a
significant number of patients with essential hypertension
having low or suppressed levels of plasma renin activity
(96.97). However. this anticipation of upward of 20'7l' of
patients with essential hypertension having normokalemic
hyperaldosteronism was not borne out and, at present. there
is no tangible explanation for the state of low renin essential
hypertension.
As indicated, a significant number of patients with es-
sential hypertension have low plasma renin activity and. in
at least some cases. the condition is volume-dependent
( 109.110). It has been asked why. in the presence of reduced
participation of the renopressor system. there is a normal
adrenal cortical response and a normal plasma aldosterone
level or aldosterone excretion. To answer this question.
some investigators suggested altered responsiveness of the
adrenal cortical cell to angiotensin II stimulation ( III l. and
others suggested an additional. as yet unknown. adrenal
cortical hormone ( 112l. Evidence in favor of the latter pos-
sibility was offered by the occasional findings of newer
adrenal steroid substances having weaker sodium-retaining
ability (113). and by the normalization of arterial pressure
in patients with this condition by treatment with certain
agents that arrest all biogenic steroidogenesis pharmacolog-
ically (114). In any event. clinical and experimental inves-
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tigations in this area of the renin-angiotensin-aldosterone
system have been among the most intense in the field of
hypertension over the past 25 years (and clearly among the
most productive).
Other mechanisms. Vasopressin. It is clear that other
mechanisms participate in the control of arterial pressure
(Table 1). Although several have been known for some time
to participate physiologically in bodily homeostasis, until
recent years their effect in hypertensive diseases had not
been studied. Thus, we have known that vasopressin has
important implications in the homeostasis of total body water
and also has the ability to produce arteriolar constriction.
Recent studies have shown that vasopressin may be in-
creased in certain forms of experimental hypertension (115),
but this has not yet been shown in human beings (116).
Now that methods are available for measurement of this
substance, further information will no doubt be forthcoming.
Prostaglandin system. Much has been reported concern-
ing the biochemistry and biosynthesis of the many naturally
occurring prostaglandin substances (117,118). Some of these
compounds are vasoactive and may produce vasoconstric-
tion or vasodilation (119,120), but at present there is in-
sufficient information to incriminate anyone of these agents
in the pathogenesis of hypertension. We do know, however,
that the prostaglandin system interrelates importantly with
the renopressor system (121) and that this relation may be
demonstrated in the different hypertensive conditions and
in the normotensive pathophysiologic state of Bartter's syn-
drome (122).
Kallikrein-kinin system. Not only is the renopressor
system interrelated with the prostaglandin and adrenergic
nervous systems, but there is also an interrelation with the
kallikrein-kinin system (123). Indeed, these two systems
share the same enzyme system that activates and inactivates
their pressure-mediating agents: the converting enzyme that
cleaves the terminal two amino acids from the inactive de-
capeptide angiotensin I to form the potent octapeptide va-
soconstrictor and aldosterone-stimulating agent angiotensin
II which inactivates circulating bradykinin, the potent va-
sodepressor agent (124). Other actions of the prostaglandin
and kallikrein systems as they might relate to the control of
arterial pressure are their roles in sodium balance (125) and
in clotting (126).
Depressor role of kidney. Over these past several dec-
ades, studies have described a depressor role of the kidney.
Indeed, participation of the kidney in maintaining volume
homeostasis has been shown to be defective in renoprival
forms of hypertension. This is best manifested clinically by
the anephric patient whose arterial pressure levels can be
controlled by the state of filtration pressure during hemo-
dialysis and by the sodium balance of the patient (127). In
addition, a remarkable series of studies by Muirhead and
his colleagues (128) has implicated the presence of a renal
medullary nonprostaglandin lipid substance that acts as a
depressor agent. Investigation progresses in this area, which
may also have important clinical implications for the future.
Sodium. As indicated, the sodium ion seems to have a
major role in the pathogenesis of hypertension (129). This
finding received greatest impetus from: 1) epidemiologic
studies pointing to the greatest prevalence of hypertension
in populations that have the greatest dietary sodium intake
(21-27); 2) experimental studies that indicated aggravation
of certain types of hypertension with increasing sodium
intake (130-133); and 3) clinical studies that showed the
increasing arterial pressure with a large sodium intake in
patients with borderline hypertension (134) and the better
control of arterial pressure in patients treated with sodium-
depleted diets (135).
There has been a series of studies that seems to point to
an abnormality in sodium transport across the cellular mem-
brane in patients with essential hypertension (135-138).
Studies recently demonstrated this defect in the sodium-
potassium-adenosine triphosphatase system of red blood cells
of patients with essential hypertension (but not in patients
with renal artery disease) (139,140), suggesting that a ge-
netic mechanism might be related to the pathogenesis of
essential hypertension. The same defect has also been found
in genetically (spontaneously) hypertensive rats, suggesting
an inherited enzymatic regulation of intracellular sodium
and potassium exchange (141).
Natriuretic hormone. In this regard, it is appropriate to
raise the concept of the still to be defined' 'third factor" or
natriuretic hormone that may participate in the pathogenesis
of hypertension (142,143). This substance has been sug-
gested to be produced in extrarenal areas in the brain (144)
and possibly in the left atrium (145,146). This substance
might operate inappropriately in hypertension, producing an
altered sodium balance in the hypertensive patient through
its renal excretory mechanism and setting in motion some
of the mechanisms discussed earlier. An alternative hy-
pothesis has been suggested in which an alteration in the
sodium-potassium-adenosine triphosphatase exchange mech-
anism results in an increased vascular resistance and
arterial pressure (147). In this context, the exchange defect
results in increased intracellular movement of calcium ions
that serves to increase the smooth muscle tone and hence
arteriolar resistance (148).
Obesity. As indicated earlier, other factors recognized
clinically also seem to participate in the elevation of arterial
pressure. Studies over the past 25 years (38-41) have pointed
to an important role of body mass. Initially, workers sug-
gested that perhaps the greater arm girth of obese persons
produced factitious and abnormally high arterial pressure
readings. Although this has some effect, it does not entirely
account for the association between obesity and high blood
pressure. Others have suggested that the excessive food
intake associated with the maintenance of the obese state is
related to sodium excess and this, too, most likely has some
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effect. However, more recent prospective clin ical studies
have show n that body mass. itsel f. no doubt also plays an
impo rtant role (149 , ISO). In these latter studies . patients
demonstrated a reduction in arterial pressure on calorie-
restricted diet s that were augmented by sodium intake to
pred ietary treatment levels (149); this reduced pres sure was
related to an increased circulating volume and card iac output
(! 50 .151 ). Just how increase d body mass, but not neces-
sarily fatty tissue , elevates arte rial pressure is not known .
Altered adrenergic participat ion ( 152) and participation of
the sodium-potassium-adenosine triphosphatase system (153)
have been suggested . Thi s is yet another area that will de-
serve investigative attention over the next several year s.
Diagnosis
As with so many other area s of cardiovascular medicine.
the management of hypertensive diseases has benefited greatly
over the past 25 years from newer diagnostic techniques.
Obviously , without the careful and frequent measurement
of arteria l pressure using ihe most ubiqu itous nonin vasive
cardiovascular instrument, the sphygmomanometer. no di-
agnosis would be possible . Thu s. it will always be imper-
ative for all physicians to measure , record and compare with
previous measurements the blood pressure of all patient s
seen in the office .
Selective catheterization and arteriography. One of
the most important diagnostic methods develop ed durin g
the 1960s was that of selective arteriography. Thi s techn ique
permits ca reful radiograph ic diagnosis of renal artery dis-
eases and the identification of patient s with renovascular
hypertension . With extensive experience . a radiographic
classification of renal artery lesions was developed that sug-
gested not only the pathogenesis of the disease but its natural
history 054.(55). Patients with atherosclerotic renal artery
lesions mayor may not have causally associated hyperten-
sion. but it is more likely that in patient s with nonather-
osclerotic lesions of renal arteries. the hypertension is causally
related to the renal artery lesion through participat ion of the
renopressor sys tem (156 ,157). Moreover. these studies per-
mitted some prognosis of the complications of the lesions.
For exa mple . pat ient s with the so-ca lled string of beads
lesion of medial fibroplasia more than likely had a slow ly
progressing disease that was not infrequently bilateral. In
contrast, other fibrosing lesions may be associated with a
greater frequency of obstruct ion from thromb osis , dissection
and aneurysm formation.
The techn ique of selective angiog raphy soon permitted
renal vein renin sampling for determining plasma renin ac-
tivity and preoperative pred iction of surgical correctab ility
of the vasc ular lesion (83-85) . These radiologic techn iques
also permitted the use of selective adrenal venography and
blood sampling for hormone levels (I58).
Measurement of humoral factors. Diagnosis of var-
ious form s of hypertension has been remarkably enhanced
with the development of radioimmunoassay techniques ( 159).
Thi s methodology has perm itted more physiologic sampling
and accurate measurements requ iring only small amounts
of blood for the determinat ion of plasma levels of plasma
renin activity , angiotensin II (still restricted to only a few
research laboratorie s). angiotensin-converting enzyme. va-
sopress in, aldosterone and other adrenal steroidal horm ones
and many other substances . In addition. radioenz ymatic
techn iques have permitted measurement of plasma levels of
the different circulating catecholamines (78). in regard to
these methods, it is important to reiterate the frequently
stated clinical warning that any or all medications that pa-
tient s take (including oral contrace ptives) may affect these
measurements. Other factors may also alter the accuracy of
these measurements. including the time of day when the
blood is sampled. whether or not the patient is fastin g .
whether the patient is in the supine or upright posture. whether
the patient has recentl y smoked a cigarette and the time in
the menstrual cycle . Part icularly for the cardiovascular phy-
sicia n who collects blood samples by catheterization. care
must be exe rcised in the choice of anticoagulant age nt for
the sample and whether the sample tube must be placed
immediate ly in an ice bucket and then promptly centrifuged
in a co ld environment.
Newer radiographic techniques. In recent years. the
developm ent of digital subtrac tion angiography has per-
mitted arter iographic visualization of the renal and other
arteries. perm itting outpatient diagnosis of renal (as well as
caro tid and peripheral) artery lesions using intravenous in-
jec tion of contrast mater ial ( 160). Although this technique
is still new and the equipment is not yet in widespread use .
its value in defining arterial lesions in patients with hyper-
tension is great, particularly in this era of awareness of cos t
effectiveness for diagnostic procedures without costly
hospitalizations.
Computed axial tomography . Another recently devel-
oped technique. computed axial tomography (CAT scan-
ning), is particularly usefu l as a key means of diagnosis of
adrenal tumors (especially pheochromocytoma) ( 16 1). As
an outpatient techn ique , it is compatible with efforts to atta in
improved cos t effectiveness. Its diagnostic effectiveness can
be enh anced with the measurement of plasma catecholamine
levels . This technique is also useful for recognition of other
types of adrenal tumors. alihough the diagnostic value is
less great because some of these tumors may be extremely
minute .
Echocardiography in left ventricular hypertrophy.
Echocardiographic techn iques have become a major diag-
nostic aid in cardiology , and in rece nt years have provided
accu racy in definin g left ventricular hypert roph y in hyper-
tension ( 162). Thu s. although establishment of the presence
of left ventricular hypertrophy is a rathe r simple procedure
once it is obvious by electroca rdiographic and roent geno-
gra phic criteria (163). these arc less precise in the earlier
stages (162.164.165). Electrocardiographic criteria are more
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sensitive than X-ray measurements (163). but echocardiog-
raphy is still more sensitive with respect to early involve-
ment (162,164,165). In addition, echocardiography is par-
ticularly useful in patients with persistently high office blood
pressure readings, whose electrocardiogram and chest X-
ray films fail to show evidence of ventricular enlargement.
thereby suggesting a lack of persistently elevated pressures.
Thus, when echocardiographic measurements fail to dem-
onstrate increased ventricular wall thickness or mass. it is
unlikely that the office pressure readings remain persistently
elevated over a 24 hour period.
Moreover, studies in animals with experimental hyper-
tension (166-170) and more recent studies in patients
(171, 172) suggest that certain antihypertensive agents will
produce regression of left ventricular hypertrophy. Indeed,
agents that produce such regression may have less impres-
sive hemodynamic effects (for example, methyldopa, beta-
adrenergic blocking agents) than more potent or seemingly
more beneficial antihypertensive agents (hydralazine and
minoxidil, for example) that fail to cause regression of (or
that even aggravate) left ventricular hypertrophy (169). While
these findings are intriguing, they are confusing in the light
of existing knowledge, and they definitely require more
careful experimental and clinical investigation. This might
be particularly important when the abrupt rise of arterial
pressure that occurs with discontinuance of antihypertensive
medication (173) is considered, particularly since there are
no data available concerning the performance ability and
function of the left ventricle with regressed hypertrophy after
the arterial pressure has risen. At this time, experimental
studies indicate that left ventricular pumping ability is nor-
mal after regression of left ventricular hypertrophy (168,170):
however, the ventricle has a greater percentage of collagen
after regression than before regression ( 174), and the pump-
ing ability studies have been reported only for function at
normal levels of arterial pressure.
Clinical Therapeutic Trials
Perhaps no area of clinical investigation has yielded more
outstanding dividends in demonstrating efficacy of reduced
overall morbidity and mortality than the prospective mul-
ticenter clinical trials of antihypertensive agents. Although
extremely costly, these studies first demonstrated the effi-
cacy and safety of the wide variety of antihypertensive agents.
The contributions of the many pharmaceutical houses in this
area are obvious, for it has been through this means of
multicenter studies that larger numbers of patients have been
subjected to larger scale screening and treatment programs
that eventually permit the widespread use of effective an-
tihypertensive agents. These studies have been designed to
obtain approval by governmental regulatory bodies for com-
mercial availability.
Early multicenter trials. Lessons learned from this ap-
proach were applied by pioneering clinical investigators in
small scale clinical trials that demonstrated the efficacy of
the early antihypertensive agents in reducing arterial pres-
sure and cardiovascular morbidity and mortality (175-178).
Soon multicenter studies designed by clinical investigators
independent of commercial constraints were instituted: the
most notable of these were the now classic trials of the U.S.
Veterans Administration under the careful chairmanship of
Freis (179,180). These studies initially demonstrated the
efficacy of the potent ganglionic blocking agents in patients
with severe hypertension and the synergistic value of the
thiazide diuretic agents with reserpine or with additional
hydralazine. Once the feasibility of the multicenter study
involving investigators of wide geographic spread but with
central administrative and statistical support was estab-
lished, a series of studies was undertaken to demonstrate
the validity of antihypertensive therapy in reducing mor-
bidity and mortality. Using the same combination of antihy-
pertensive agents shown early to be safe and efficacious
(with an appropriate randomly selected, placebo-treated
control group), the Veterans Administration Cooperative
Study Group first demonstrated the validity of therapy in
patients whose diastolic pressure exceeded 114 mm Hg at
the onset of the study (18\). Next. value of therapy was
demonstrated in patients whose diastolic pressures exceeded
104 mm Hg (182): there were too few patients whose pre-
treatment diastolic pressures were within the 90 to 105 mm
Hg range.
Later trials. As a result. a number of subsequent studies
were designed to attack the problem of so-called mild hy-
pertension. The first reports came from the Hypertension
Detection and Follow-up Program ( 183, t84). This 14-center
study involved approximately II ,000 patients screened from
an overall population of more than 180,000 persons allo-
cated into two treatment groups. One group received stan-
dard medical treatment prescribed by community physicians
(referred care group) and this therapy included all available
health care and antihypertensive agents. The other group
received a programmed stepped-care treatment program fol-
lowed by algorithm by a health care team that was chal-
lenged to provide as intensive a therapy as possible using
whatever available techniques could be mustered to maintain
blood pressure control. These techniques included estab-
lishment of pretreatment pressure goals, provision of free
medication, transportation to clinics (if necessary), profes-
sional follow-up of missed appointments and so forth. Within
5 years, the program demonstrated lower overall and car-
diovascular morbidity and mortality rates in patients with
all levels of blood pressure elevation including those with
mild blood pressure elevation (90 to 104 mm Hg).
These reports were soon supported by studies from Aus-
tralia and Norway (using placebo-treated, randomly selected
patients) which demonstrated similar improvement in mor-
bidity and mortality in patients with mild hypertension ( 185,
186). Not only was the value of those antihypertensive agents
used in the Veterans Administration trials demonstrated, but
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also included were other diuretic agents. the beta-adrenergic
receptor blocking drugs and adrenolytic agents.
At the time of this writing. several other multicenter
investigations are in progress (187 J. One study is designed
to learn the value. if any. in improving overall morbidity
and mortality by reduction of other cardiovascular risk fac-
tors such as obesity. cigarette consumption. hyperlipidemia
and control of diabetes (the so-called MRflT Trial). Others
(organized by treatment centers in Western Europe) are de-
signed to learn whether there is benefit from treating hy-
pertension in the elderly patient and some (organized by the
U.S. National Institutes of Health) are investigating isolated
systolic hypertension.
Effect of blood pressure control. This report is not
intended to provide a comprehensive overview of all clinical
trials involving the use of antihypertensive agents. but in
my estimation the prospective therapeutic intervention trials
mentioned have provided the outstanding landmarks for our
present "state of the art" and improved cardiovascular health
derived from an enlightened approach to the treatment of
hypertension. Indeed. at the beginning of the 1970s it was
estimated that only about one of eight patients with hyper-
tension was receiving effective antihypertensive therapy.
The number of patients under treatment has since been vastly
increased (188). As a result. it seems fair to say that blood
pressure control has. at least in part, accounted for a re-
duction in the U.S. national cardiovascular mortality from
54 to 50% of all deaths and a 33% reduction in the number
of strokes (188). Clearly. this is one of the major challenges
for an enlightened era of preventive cardiology as we near
the 21st century.
Therapeutic Agents
One cannot review the accomplishments in the area of hy-
pertension over the past 25 years and neglect the fact that
during this period, a remarkable array of agents has been
developed. Not only have they had an impact on the treat-
ment of hypertension but clinical investigators and the phar-
maceutical industry, working as a therapeutic team. have
provided major innovations with these drugs for the treat-
ment of: I) heart failure (through diurectic agents, vasodi-
lators and converting enzyme inhibitors): 2) angina pectoris
(through diuretic agents, the concept of blood pressure re-
duction. beta-adrenergic receptors and calcium channel in-
hibitors: 3) cardiac arrhythmias (through concepts intro-
duced concerning hypokalemia. the beta-adrenergic receptor
blocking agents and sympatholytic agents); and 4) other
cardiovascular problems. Therefore. what might be appro-
priate in this report of the highlights of this " golden era of
hypertension" is a review of the development of this pro-
ductive area. pointing toward new anticipated areas of
therapeutics.
Already available for the practicing physician 25 years
ago was the concept that there was nothing "essential" to
the clinical problem of hypertension. Contrary to the earlier
held concept that " essentielle hypertonic" was necessary
to perfuse the vital organs. the therapeutic pioneers clearly
demonstrated the value of arterial pressure reduction in pa-
tients with severe hypertensive states using the rice-fruit diet
(189). ganglionic blocking agents (190), sympathectomy
(1 91) and the veratrum alkaloids (192l and reserpine (193).
Pyrogen therapy and renal extracts (1 94) had already been
discarded in favor of these new approaches.
Diuretics. Thiazides , The modern antihypertensive
therapeutic era was born with the introduction of a new
effective and potent long-acting agent by Novello and Spra-
gue (195) that produced impressive natriuresis and diuresis
associated with an impressive reduction of arterial pressure
(196.197) . Introduction of this agent. chlorothiazide. was
soon followed by the synthesis of a vast array of related
halogenated congeners of the thiazide group. Although they
differ from each other by chemical structure and certain
other characteristics. their physiologic similarities are great.
All first produce a natriuresis and contracted plasma (and
extracellular fluid) volume associated with a reduced cardiac
output. followed by a reduction in pressure and decreased
total peripheral resistance (198.199) associated with a vas-
cular attenuation of pressor stimuli and potentiation of de-
pressor stimuli (200). The thiazides are associated with a
relatively narrow dose-response curve. Each agent is ex-
pected to produce some degree of decrease in glomerular
fi ltration rate associated with natriuresis. kaliuresis. hypo-
kalemic alkalosis. secondary hyperaldosteronism and vari-
able rises in plasma uric acid and glucose levels (20 1l.
Other agents. The so-called loop-acting agents (etha-
crynic acid and furosemide) acting at the ascending thick
limb of the loop of Henle. have a much broader dose-
response relation and are of value in patients with impaired
renal function (202). Other agents have been synthesized to
provide an active means to retain potassium in response to
the kaliopenic effects of the thiazide congeners and the loop-
acting diuretic agents. Spironolactone achieves this through
an active inhibition of aldosterone's action at the distal tu-
bule (203). whereas the other two agents in use today pre-
serve potassium through an amiloride-like effect at the distal
tubule that inhibits the sodium for potassium exchange
mechanisms (204). Of the two latter agents currently avail-
able. triamterene and amiloride, the latter is the more potent
in reducing pressure (205).
Adrenergic inhibiting agents. Shortly after the intro-
duction of the thiazide diuretic agents. a remarkable new
group of drugs was synthesized. These provided more spe-
cific inhibition of the sympathetic nervous system than the
ganglionic sympathetic inhibition in patients with severe
hypertension without producing such central nervous system
effects as mental depression (206.207). It was now possible
to achieve blood pressure control without necessarily in-
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ducing impotence or paralytic ileus. Problems of postural
hypotension and reduced organ perfusion to brain, heart and
kidney were soon obviated by the introduction of methyl-
dopa (208).
Methyldopa and clonidine. At this point. it is appropriate
to cite the information added to our concept of adrenergic
receptors introduced by Alquist (209) in 1948. Alpha-ad-
renergic receptors, when stimulated by the neurohumoral
substance norepinephine , produced vasodilation, whereas
beta-receptor stimulation produced vasodilation and an in-
crease in heart rate and myocardial contractility and metab-
olism (210). Soon beta-receptors were subclassified as betal-
receptors in the heart and kidney, and beta--receptors in
vessels, bronchi, the gastrointestinal tract and elsewhere.
Alpha-receptors usually were found on vascular smooth
muscle cellular membranes at postsynaptic loci mediating
vasoconstriction, but they may also be found at presynaptic
loci. When alphayreceptors are stimulated, they inhibit the
release of catecholamines from the adrenergic nerve ending
as do certain centrally acting postsynaptic receptor stimu-
lating agents (211-213). As a result of the newer infor-
mation, we are now provided with our current understanding
of the action of the central adrenergic inhibitors. Clonidine
stimulates central alpha-receptors at the nucleus tractus so-
litarius, whereas methyldopa must first be metabolized in
the neurons of this nucleus to alpha-methylnorepinephrine,
which in turn provides the alpha stimulation that inhibits
cardiovascular outflow from the hindbrain (212-214). Sev-
eral additional centrally acting adrenergic inhibitors are un-
der study, but for the purpose of this review they offer no
major conceptual addition to the overall understanding of
the central mechanisms of the antihypertensive therapeutic
agents.
Phentolamine, phenoxybenzamine. prazosin and urapi-
dil. Early in the history of adrenergic inhibitors was the
synthesis of two compounds, phentolamine and phenoxy-
benzarnine. agents that we now know to inhibit both pre-
and postsynaptic alpha-receptors (215). These agents lower
arterial pressure associated with reflexive stimulation of the
heart. However, the postsynaptic alphaI-receptor blocking
compound prazosin produces hypotension without reflexive
tachycardia, suggesting an additional action to that of pe-
ripheral alpha.vreceptor inhibition (216). A new and intrigu-
ing agent, urapidil, recently synthesized in Europe, is said
to have actions of the peripheral alpha-receptor inhibition
of prazosin and the central postsynaptic alpha-receptor stim-
ulation of clonidine and alpha-methylnorepinephrine (217).
Beta-adrenergic receptor inhibition. Soon after intro-
duction of the thiazide compounds, a new series of adre-
nergic inhibiting drugs was made available that reduced
arterial pressure through inhibition of beta-receptor sites
(218). However, several years elapsed before the compound
propranolol was made available and was shown by Prichard
and Gillam (219) to be effective in reducing arterial pres-
sure. Although widely postulated to reduce pressure by
"resetting baroreceptors" (220,221), this mechanism has
not been substantiated nor has the mechanism that operates
through reduced cardiac output (222) or inhibition of renin
release from the kidney (99). Patients not responding to
beta-adrenergic blocking therapy with a pressure reduction
may also have a reduced cardiac output (223), and other
patients treated with beta-adrenergic receptor blocking drugs
having intrinsic sympathomimetic activity may not dem-
onstrate inhibition of renin release (224). Therefore, like
the diuretic agents, the beta-adrenergic receptor blocking
agents continue to challenge the investigator for elucidation
of a valid antipressor mechanism.
Vasodilators. Calcium inhibitors. For many years the
clinician has been offered a most simplistic explanation for
the action of such disparate vasodilators as hydralazine.
diazoxide, minoxidil and nitroprusside. These agents have
been thought to lower arterial pressure by decreasing vas-
cular smooth muscle tone, but how this is achieved still
must be explained. Why only nitroprusside acts on both
venules and arterioles remains unexplained. In recent years.
a new but inhomogeneous group of the vasodilators has
been introduced. Although currently used only for the treat-
ment of angina pectoris in the United States, these so-called
slow channel calcium inhibitors act by preventing the in-
tracellular movement of calcium ions from the extracellular
space (225). One agent, verapamil, possesses antiar-
rhythmic activity to slow supraventricular tachycardias (226),
but this action is not possessed by the vasodilator nifedipine
(227); both actions may be found with diltiazem and ni-
trendipine (228,229). We may be on the brink of a new era
in our understanding of vascular smooth muscle function as
our experience with these agents broadens.
Inhibitors of the renopressor system. Captopril. An
active academic intellectual discussion of the 1970s sur-
rounded the practicality of the renopressor system. With the
availability of a wide variety of pharmacologic agents that
inhibit this system at many levels, the empiric participation
of this system in hypertension becomes obvious. Adrenergic
inhibiting drugs (including most beta-adrenergic receptor
blocking agents) inhibit renin release from the kidney, thereby
preventing the formation of angiotensin I from its substrate
angiotensinogen. More recently, a second level of inhibition
has been achieved with the synthesis of agents that inhibit
the angiotensin-converting enzyme, thereby preventing the
cleavage of the terminal two amino acids from angiotensin
I to form the potent pressor octapeptide angiotensin II. Al-
though several angiotensin-converting enzyme inhibitors have
been synthesized, only one such agent is commercially
available, captopril; another, enalapril maleate (MK-421),
is under active clinical investigation throughout the world
(230). At this point, the most logical antihypertensive mech-
anism is inhibition of the formation of angiotensin It how-
ever, since the angiotensin-converting enzyme is the very
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same enzyme that degrades the naturally occurring potent
vasodilating agent bradykinin (124), this action also is pos-
sible. Furthermore, because angiotensin II stimulates al-
dosterone production and augments central and peripheral
adrenergic outflow to the cardiovascular system, inhibition
of these mechanisms is also possible . One additional novel
compound capable of inhibiting the renopressor system is
saralasin , a sympathetic analog of angiotensin II that com-
petitively inhibits the action of angiotensin II at vascular
receptor sites (231).
Conclusions
Cardiovascular medicine has matured greatly over the past
25 years. To one interested in hypertension, it is clear that
the investigation of this major cardiovascular problem has
provided its share of knowledge and benefits to humanity.
Physicians have moved from a position of passive obser-
vation of an elevated arterial pressure to an active role in
identifying patients with even mildly elevated pressures in
an effort to put into practice that which is now feasible:
control of pressure at normotensive levels so that significant
improvement of morbidity and mortality can be achieved.
This is possible with an impressive array of new diagnostic
methods and techniques and a wide variety of pharmacologic
agents that can specifically inhibit most naturally occurring
mechanisms. Nevertheless , the clues from both older and
more recent research augur well for the future of new knowl-
edge and more improved therapy that will continue to bring
excitement and satisfaction to the practice of cardiovascular
medicine .
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